August 29, 2018
Mylan Institutional Inc. is voluntarily recalling 408 cartons of 120-mg diltiazem hydrochloride extended-release capsules, USP, 80 capsules, 8 blister cards of 10 capsules each per carton (NDC 51079-947-08). The recalling firm also does business as UDL Laboratories.
According to the August 29, 2018, US Food and Drug Administration (FDA) Enforcement Report, the recall is for capsules from batch 3096049. Samples from the batch tested out of specification for a compound.
Cartons affected by the recall, which was initiated August 14, 2018, were distributed across the United States. On August 22, 2018, the FDA designated the recall Class III, signaling use of the recalled drug is not likely to cause harm.
Diltiazem hydrochloride is a prescription calcium channel blocker used for the treatment of high blood pressure, chest pain, and some heart rhythm disorders.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here